Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial.
暂无分享,去创建一个
E. Antman | R. Giugliano | E. Braunwald | Sungha Park | B. Bergmark | N. Chung | C. Ruff | H. Lanz | M. Shi
[1] S. Yusuf,et al. Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial). , 2015, The American journal of cardiology.
[2] G. Stergiou,et al. Automated blood pressure measurement in atrial fibrillation: a systematic review and meta-analysis , 2012, Journal of hypertension.
[3] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[4] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[5] E. Antman,et al. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis. , 2016, Journal of the American College of Cardiology.
[6] G. Breithardt,et al. Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial. , 2016, American heart journal.
[7] E. Antman,et al. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. , 2016, The American journal of medicine.
[8] J. Coresh,et al. 60 A comparison of HFrEF vs HFpEF’s clinical workload and cost in the first year following hospitalisation and enrollment in a disease management program , 2016, Journal of the American College of Cardiology.
[9] T. Osaka,et al. Impact of Blood Pressure Control on Thromboembolism and Major Hemorrhage in Patients With Nonvalvular Atrial Fibrillation: A Subanalysis of the J‐RHYTHM Registry , 2016, Journal of the American Heart Association.
[10] G. Lip,et al. Effect of hypertension on anticoagulated patients with atrial fibrillation. , 2007, European heart journal.
[11] Deepak L. Bhatt,et al. Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk , 2018, European heart journal.
[12] Jackson T. Wright,et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American College of Cardiology.
[13] C. Peralta,et al. Blood Pressure in Older Adults: the Importance of Frailty , 2015, Current Hypertension Reports.
[14] D. Lane,et al. Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores , 2016, Journal of thrombosis and haemostasis : JTH.
[15] E. Antman,et al. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial , 2016, Journal of the American Heart Association.
[16] G. Stergiou,et al. Automated blood pressure measurement in atrial fibrillation: a systematic review and meta-analysis. , 2013, Journal of hypertension.
[17] R. de Caterina,et al. Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial , 2015, Journal of the American Heart Association.
[18] J. Halperin,et al. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. , 1998, Journal of the American College of Cardiology.
[19] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[20] D. Singer,et al. Gender Differences in the Risk of Ischemic Stroke and Peripheral Embolism in Atrial Fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study , 2005, Circulation.
[21] Giuseppe Mancia,et al. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group ‘Hypertension Arrhythmias and Thrombosis’ of the European Society of Hypertension , 2012, Journal of hypertension.
[22] G. Breithardt,et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). , 2014, Journal of the American College of Cardiology.
[23] G. Mancia,et al. Clinical Outcomes in the Diabetes Cohort of the International Verapamil SR-Trandolapril Study , 2004, Hypertension.
[24] G. Lip,et al. Ideal Blood Pressure in Patients With Atrial Fibrillation. , 2018, Journal of the American College of Cardiology.
[25] E. Antman,et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). , 2010, American heart journal.
[26] M. Woodward,et al. Effects of Blood Pressure Lowering on Intracranial and Extracranial Bleeding in Patients on Antithrombotic Therapy: The PROGRESS Trial , 2012, Stroke.
[27] S. Schulman,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.
[28] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.